HOME >> BIOLOGY >> NEWS
Immunity gene predicts severe adverse drug reaction

DURHAM, N.C. -- In a study of Han Chinese patients, researchers have for the first time directly linked a gene of the immune system to a severe adverse drug reaction called Stevens-Johnson syndrome (SJS), according to a Duke University Medical Center medical geneticist and collaborators in Taiwan.

The sometimes fatal condition is characterized by a blistering rash that can lead to detachment of the skin and inflammation of the gastrointestinal and respiratory lining. More than 100 drugs -- including antibiotics, NSAIDS, anticonvulsants and the gout drug allopurinol -- are known to cause SJS in rare cases. The frequency with which particular prescriptions spur the devastating reaction varies among people of different ethnic backgrounds.

Their new test for the predisposing gene could be applied almost immediately to determine which of the 1.2 billion Chinese worldwide would be at risk for the reaction to the popular anti-epilepsy drug carbamazepine (trade name Tegretol), said Y-T Chen, M.D., chief of medical genetics at Duke University Medical Center and director of the Institute of Biomedical Sciences at Academia Sinica in Taiwan. The anticonvulsant is the most common cause of SJS among the Chinese population.

The finding highlights the promise of pharmacogenomics for avoiding drugs' most serious side effects and might also lead to advances in the clinical trial of new drugs, said the researchers.

A single genetic marker predicted with 100 percent accuracy those who could safely take carbamazepine, the team reported in the April 1, 2004, issue of Nature. Individuals with a particular version of the immunity gene who took the drug suffered the devastating reaction in all but 3 percent of the cases.

Whether the gene variant will predict the drug reaction in people of other ethnic backgrounds remains to be tested, said Chen. However, his team expects that other similar genes will be found to underlie the reaction induced by the ma
'"/>

Contact: Kendall Morgan
kendall.morgan@duke.edu
919-684-4148
Duke University Medical Center
1-Apr-2004


Page: 1 2 3

Related biology news :

1. Clues To Transplant Tolerance Linked To Infectious Disease Immunity Cell Traffic Key, Say Authors In New England Journal of Medicine
2. Neurons Control Brain Immunity: Neurotrophins As Regulators Of Antigen-Presentation In Microglial Cells
3. Fetal Lead Exposure May Reduce Immunity
4. Hardy buoys: Texas A&M project predicts oil spill movements
5. New tool predicts how long pollutants will stay in soil
6. Molecular marker predicts success of breast cancer treatment
7. Is that plant a tortoise or a hare? Answer predicts its response to environmental change
8. Brain signal predicts working memory prowess
9. New software developed at Rensselaer predicts promising ingredients for new drugs
10. New map predicts where wolves will attack
11. Study predicts conditions for sustainable lion trophy hunting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Immunity gene predicts severe adverse drug reaction

(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... year, carrying more than 284 million tons of cargo, transit ... in toll fees for the Panama Canal Authority. Each time ... water are used from Gatun Lake, which is also a ... the isthmus. , However, the advent of very large ... ships at sea, has demanded change. The Panama Canal is ...
(Date:5/23/2013)... The tight wrapping of genomic DNA around nucleosomes ... gene expression. A team of Ludwig-Maximilians-Universitaet (LMU) in ... DNA to be locally displaced from nucleosomes for ... is stored in the cell nucleus, wrapped around ... pairs of four different histone proteins and accommodating ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Biochemistry: Unspooling DNA from nucleosomal disks 2
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a ... research and development, sales and marketing of premium ... today that it is awarding exclusive Vestiage territories ... Reluma Skin Illuminating Facial Care. Qualified applicants can ... an email to info(at)vestiageinc(dot)com and putting RELUMA in ...
(Date:5/23/2013)... 2013  BioScrip, Inc. (NASDAQ: BIOS ) ... Jefferies 2013 Global Healthcare Conference to be held June ... Richard Smith , President and ... , Chief Financial Officer, will present on Monday, June ... About BioScrip BioScrip, Inc. provides comprehensive ...
(Date:5/23/2013)... BROWNSBURG, Ind. , May 23, 2013  Rahal ... leader in human cord blood stem cell banking and ... sponsor of the No. 16 Acorn Stairlifts Indy car ... is for the remainder of the IZOD IndyCar 2013 ... Racing (RLL) will work to support awareness of umbilical ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
Cached News: